Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 14, 2007, Pages 3900-3904

  Zhu, Bin ^a   Marinelli, Brett A ^a   Abbanat, Darren ^a   Foleno, Barbara D ^a   Bush, Karen ^a   Macielag, Mark J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antibacterial; Erythromycin A; Ketolide; Macrolide

Indexed keywords

3 KETO 6 O CARBAMOYL 11,12 CYCLIC THIOCARBAMATE ERYTHROMYCIN; ANTIINFECTIVE AGENT; CETHROMYCIN; ERYTHROMYCIN DERIVATIVE; TELITHROMYCIN; THIOCARBAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 34250342504     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.104     Document Type: Article

References (14)

1. Bryskier A.J., Butzler J.-P., Neu H.C., and Tulkens P.M. Macrolides. Chemistry, Pharmacology and Clinical Uses (1993), Arnette Blackwell, Paris
2. Amsden G.W. J. Antimicrob. Chemother. 44 (1999) 1
3. Lonks J.R., Garau J., and Mederios A.A. J. Antimicrob. Chemother. 50 (2002) 87
4. For recent reviews, see:. Zhanel G.G., Dueck M., Hoban D.J., Vercaigne L.M., Embil J.M., Gin A.S., and Karlowsky J.A. Drugs 61 (2001) 443
5. Blondeau J.M., DeCarolis E., Metzler K.L., and Hansen G.T. Expert Opin. Investig. Drugs 11 (2002) 189
6. Kaneko T., McArthur H., and Sutcliffe J. Expert Opin. Ther. Patents 10 (2000) 403
7. For recent reviews, see:. Wu Y.-J., and Su W.-G. Curr. Med. Chem. 8 (2001) 1727
8. Zhanel G.G., Walters M., Noreddin A., Vercaigne L.M., Wierzbowski A., Embil J.M., Gin A.S., Douthwaite S., and Hoban D.J. Drugs 62 (2002) 1771
9. Asaka T., Manaka A., and Sugiyama H. Curr. Top. Med. Chem. 3 (2003) 961
10. Denis A., Agouridas C., Auger J.-M., Benedetti Y., Bonnefoy A., Bretin F., Chantot J.-F., Dussarat A., Fromentin C., Gouin D'Ambrieres S., Lachaud S., Laurin P., Le Martret O., Loyau V., Tessot N., Pejac J.-M., and Perron S. Bioorg. Med. Chem. Lett. 9 (1999) 3075
11. Ma Z., Clark R.F., Brazzale A., Wang S., Rupp M.J., Li L., Griesgraber G., Zhang S., Yong H., Phan L.T., Nemoto P.A., Chu D.T.W., Plattner J.J., Zhang X., Zhong P., Cao Z., Nilius A.M., Shortridge V.D., Flamm R., Mitten M., Meulbroek J., Ewing P., Alder J., and Or Y.S. J. Med. Chem. 44 (2001) 4137
12. Henninger T.C., Xu X., Abbanat D., Baum E.Z., Foleno B.D., Hilliard J.J., Bush K., Hlasta D.J., and Macielag M.J. Bioorg. Med. Chem. Lett. 14 (2004) 4495
13. Xu X., Henninger T., Abbanat D., Bush K., Foleno B., Hilliard J., and Macielag M. Bioorg. Med. Chem. Lett. 15 (2005) 883
14. The minimal inhibitory concentrations (MICs) were determined by the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) guidelines. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 5th ed.; Approved standard: NCCLS Document M7-A5, 2000.